Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Ratios

Minerva Neurosciences (NERV) Change in Acquisitions & Divestments (2016 - 2020)

Minerva Neurosciences filings provide 1 years of Change in Acquisitions & Divestments readings, the most recent being $3.0 million for Q3 2020.

On a quarterly basis, Change in Acquisitions & Divestments changed N/A to $3.0 million in Q3 2020 year-over-year; TTM through Dec 2020 was $28.4 million, a N/A change, with the full-year FY2020 number at $28.4 million, down 62.22% from a year prior.
Change in Acquisitions & Divestments hit $3.0 million in Q3 2020 for Minerva Neurosciences, down from $4.5 million in the prior quarter.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $20.9 million in Q1 2020 to a low of $3.0 million in Q3 2020.